ImmunoTherapyNews.net

Cancer immunotherapy

XagenaNewsletter
Medical Meeting
Xagena Mappa
Cardiobase

Search results for "Advanced melanoma"

Nivolumab ( Opdivo ) was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with Ipilimumab-refractory metastatic melanoma. The use of Nivolum ...


The results of the pivotal OPTiM study have shown that Talimogene laherparepvec monotherapy is the first oncolytic immunotherapy to demonstrate therapeutic benefit in a phase 3 trial for patients with ...


Nivolumab ( Opdivo ) is a programmed death-1 ( PD-1 ) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs overall survival in patients with melano ...


Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma and in other cancers. Factors predictive of response remain vaguely defined. Researchers have reported on clinical ch ...


The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In the setting of cancer, IDO pathway-mediated immune ...